Navigation Links
Clarient Reports Second Quarter Revenue Up 40 Percent
Date:8/4/2009

m the satisfaction of post-closing conditions related to the divestiture of its instrument systems business in March of 2007, was a $0.06 loss per share.

Adjusted EBITDA (defined below) for the 2009 second quarter was $2.3 million, compared to adjusted EBITDA of $179 thousand in the second quarter of 2008. For the 2009 six-month period, adjusted EBITDA was $5.2 million, versus adjusted EBITDA of $1.2 million in the prior year period.

Operating expenses were $13.0 million for the second quarter of 2009, up 29 percent from $10.1 million in the same quarter of 2008. For the first six months of 2009, operating expenses totaled $25.8 million, versus $18.8 million in the year-earlier period. The increase in operating expenses was largely related to additional sales and marketing personnel costs, increased bad debt expense, higher stock compensation expense, and legal and accounting expenses related to certain business development activities.

At June 30, 2009, the Company's cash and cash equivalents totaled $7.9 million compared with $1.8 million at December 31, 2008.

Ray Land, Senior Vice President and Chief Financial Officer, said, "As expected, we were able to complete the second tranche of our private placement of convertible preferred stock with Oak Investment Partners on May 14, 2009 which considerably strengthened our balance sheet. In addition, we collected $19.9 million in cash in the second quarter which is a 34% increase over our first quarter. This is a strong indication that our billing and collection process is improving."

Land cited continued progress in marketing programs and customer retention, combined with the early success of new product introductions, in increasing guidance for annual revenue to the range of $96 million to $101 million, as well as positive adjusted EBITDA and operating income for the year.

Andrews concluded, "Clarient'
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Clarient to Present at the UBS 2007 Global Life Sciences Conference
2. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
3. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
4. Clarient Generates 52% Revenue Increase in Third Quarter 2007
5. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
6. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
7. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
8. Clarient Reports First Quarter 2008
9. Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays
10. Clarient Renews and Expands Mezzanine Credit Facility With Safeguard
11. Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Gray HealthDay Reporter , , TUESDAY, May 21 ... was once next to impossible, but a new study ... screening with low-dose CT scans may help spot the ... patients considered at the greatest risk for lung cancer, ... getting CT scans and follow-up biopsies to confirm the ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Pathways ... who are grieving to remember and honor a loved ... of Remembrance Memorial Service, Sunday, June 2, 2013, 3-4 ... Boulevard, San Mateo, CA 94402. , The Pathways ... includes a short program with music, readings and support. ...
(Date:5/21/2013)... 2013 Not all treatments are effective ... Borderline Personality Disorder (BPD) and addiction. Dialectical Behavior Therapy ... successful for the treatment of both BPD and substance ... Ph.D., clinical director of Clearview Women’s Center for ... provide attendees of the West Coast Symposium on Addictive ...
(Date:5/21/2013)... obese patients are significantly more likely than their ... a practice that disrupts continuity of care and ... Hopkins research suggests. , The practice of "doctor ... of negative experiences with the health care system, ... unsolicited weight loss advice by providers, or improperly ...
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
Breaking Medicine News(10 mins):Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3Health News:Hospice Offers Evening of Remembrance Memorial Service in San Mateo, California 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2
... dedicated to the health and well being of children, ... (FDA) has approved an investigational new drug application; ... topical solution for the treatment of head lice. ... professionals a new choice for the treatment of head ...
... cyclists will be participating in the Memory Ride for Alzheimer's ... to fight the disease that affects more than 5 ... 11th annual Memory Ride has a personal story to tell ... who has struggled with the disease. ,The Alzheimer's ...
... is not as squeaky-clean as she appears . ,In a ... she is quite the opposite of her supposed righteous image. ... Do you think you have a squeaky-clean image? Im like, Could ... Us Weekly quoted her, as telling the mag. ,I ...
... the University of Idaho is helping to increase understanding ... identify conditions that make women prone to infections and ... problems. ,Women suffer from insidious health problems, ... send them in droves to seek medical treatment, said ...
... the occurrence of anaphylaxis between the northern and southern ... be fatal without treatment with epinephrine. The striking ... risk, currently are without explanation. The investigators hypothesize, however, ... sunshine, may play a role and that this hypothesis ...
... can relieve people of shyness, and help them socialise with ... use, and an individual can boost self-confidence just by squirting ... that the spray harnesses the powers of a feel-good hormone ... in social recognition and bonding. ,The mammalian ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Large Geographic Differences in EpiPen Prescriptions in the U. S. 2
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... 21, 2013  BioRestorative Therapies, Inc. ("BRT" or the ... on developing stem cell based therapies for various personal ... its President and CEO, will be presenting at the ... be held on Thursday, May 30, 2013 at the ... in New York City.  Mr. Weinreb,s presentation will take ...
(Date:5/21/2013)... and HENDERSONVILLE, N.C. , ... bidding procurement program for home medical equipment is ... North Carolina to lay off employees or ... quality of service and products received by Medicare beneficiaries, ... the defective and dangerous program, the Centers for ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 2North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 3North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program 4
... ABBOTT PARK, Ill., Nov. 12 Nearly one in three ... and nearly 34 million have low HDL "good" cholesterol levels. ... and trigs, Abbott has launched two Web sites: ... "Unhealthy high triglyceride and low HDL levels are factors that ...
... IRVINE, Calif., Nov. 12 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, and CareFusion ... device company, today announced a multi-year technology licensing ... capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology ...
Cached Medicine Technology:New Web Sites Educate About Triglycerides and HDL Cholesterol 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 2CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 3CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) 4
... comfortable eye protection Properly manufactured radiation ... scatter radiation. Our high quality frames and ... with minimized weight. Our lenses are made ... meet all industry standards. Most Pulse Glasses ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...
Medicine Products: